Domov › Rabdomiosarkom › Kalifornija
Klinične študije za Rabdomiosarkom v Kalifornija
7 študij za Rabdomiosarkom išče udeležence na lokacijah v Kalifornija.
Uradno besedilo študije (angleško)
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
- UCSF Benioff Children's Hospital, San Francisco
Vključevanje udeležencevFaza 1
24 Months – 18 Years · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06441331Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- UCSF Benioff Children's Hospital Oakland, Oakland
- Rady Children's Hospital, San Diego
Vključevanje udeležencevFaza 1/2
Do 30 let · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT06541262A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
- City of Hope Comprehensive Cancer Center, Duarte
- Loma Linda University Medical Center, Loma Linda
- Cedars-Sinai Medical Center, Los Angeles
- in še 4
Vključevanje udeležencevFaza 3
Do 50 let · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT07466316Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
- Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
Vključevanje udeležencevZgodnja faza 1
Starost 18 in več · Vsi spoli · Posodobljeno 31. jul. 2026 · NCT07628634PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
- Cedars-Sinai Medical Center, Los Angeles
- University of California, San Francisco, San Francisco
Vključevanje udeležencevFaza 1/2
Starost 1–30 · Vsi spoli · Posodobljeno 22. jul. 2026 · NCT06721689Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
- Stanford University, Palo Alto
Vključevanje udeležencevFaza 2
Do 22 let · Vsi spoli · Posodobljeno 15. jun. 2026 · NCT06023641Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
- Lucille Packard Children's Hospital Stanford, Palo Alto
Vključevanje udeležencevFaza 1/2
12 Months – 30 Years · Vsi spoli · Posodobljeno 19. maj 2026 · NCT04901702Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.